COVID-19

The Conversation: How did the University of Queensland/CSL vaccine fail due to 'false positive' HIV tests? A vaccine expert explains

Further clinical trials of the UQ/CSL COVID-19 vaccine candidate have been called off after phase 1 results showed that participants had returned 'false positive' HIV tests. The UQ/CSL vaccine utilises molecular clamp technology involving components of a HIV protein. These components are unable to cause a HIV infection, however participants were shown to be creating antibodies against HIV which then leads to a false positive HIV test result.

The following article confirms that no safety concerns had been identified. It suggests that researchers acted appropriately to limit unnecessary anxiety over inaccurate test results and to reinforce public confidence in a future COVID-19 vaccine program.

लेख को पूरा पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:

The Conversation: How did the University of Queensland/CSL vaccine fail due to 'false positive' HIV tests? A vaccine expert explains

द्वारा ऐलिस ब्लैक

The Conversation: People with severe allergies warned off Pfizer COVID vaccine for now. But that may change as more details emerge

As a precautionary measure, the UK medicines regulator have advised that people with a significant history of allergic reactions should not receive the Pfizer/BioNTech COVID-19 vaccine after 2 people experienced allergic reactions. The following article outlines how common allergies to vaccines are, why these types of reactions weren't noted in clinical trials and the role of ongoing safety surveillance and monitoring.

लेख को पूरा पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:

The Conversation: People with severe allergies warned off Pfizer COVID vaccine for now. But that may change as more details emerge 

द्वारा ऐलिस ब्लैक

Australian Government Department of Health: COVID-19 vaccines

The Australian Government Department of Health have developed a dedicated resource for COVID-19 vaccines. This site will host news and information for Australians about the development, approval process and plans for COVID-19 vaccines.

To access this resource, please follow the link below:

Australian Government Department of Health: COVID-19 vaccines

द्वारा ऐलिस ब्लैक

FDA report reveals phase 3 clinical trial data for the Pfizer and BioNTech COVID-19 vaccine candidate

In preparation for a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA has made public the interim results of phase 3 clinical trials for the Pfizer and BioNTech COVID-19 vaccine candidate. This meeting will discuss the Emergency Use Authorisation (EUA) application and determine any recommendations for approval.

Phase 3 clinical trials were spread across the US, Argentina, Brazil, Germany, South Africa and Turkey. The Pfizer and BioNTech vaccine candidate utilises a messenger RNA (mRNA) platform and its' studies involved participants aged 16 to  85 years. Findings have shown that the vaccine candidate has an acceptable safety profile and following the administration of 2 doses, has an efficacy rate of 95%.

To read the document in full please refer to the link below:

Vaccines and Related Biological Products Advisory Committee: FDA briefing document- Pfizer-BioNTech COVID-19 vaccine

द्वारा ऐलिस ब्लैक

The Lancet: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK

The Oxford Vaccine Trial group have published interim results for phase 3 clinical trials of their COVID-19 vaccine candidate (ChAdOx1 vCoV-19). This vaccine utilises a viral vector platform and previous phase 1/2 studies have shown an acceptable safety profile. Participants in the phase 3 trials, held across the UK, Brazil and South Africa, were aged 18y or older. Findings have shown that when participants received 2 equal doses, vaccine efficacy was 62.1%. Participants who received a lower dose followed by a standard dose, vaccine efficacy was 90.0%.

To read the article and view these results in full, follow the link below:

The Lancet: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK

द्वारा ऐलिस ब्लैक

UK authorises Pfizer/BioNTech COVID-19 vaccine

Following a thorough analysis of data produced from rigorous clinical trials, the independent Medicines and Healthcare products Regulatory Agency (MHRA) in the UK have concluded that the Pfizer/BioNTech COVID-19 vaccine meets the strict standards of safety, quality and effectiveness required. As such, the UK government has announced it's approval with plans to make the vaccine available from as early as next week. Final advice on priority groups is still being determined by the Joint Committee on Vaccinations and Immunisations (JCVI).

To read the press release please refer to the link below:

UK authorises Pfizer/BioNTech COVID-19 vaccine

द्वारा ऐलिस ब्लैक